PureTech Health plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PureTech Health plc
PureTech is among the very first companies to attempt to treat long Covid and hopes its anti-fibrosis drug can aid patients’ recovery
Public Company Edition: Three $100m-plus US initial public offerings launched on 15 July after two smaller biopharma IPOs earlier in the month. Also, Gelesis announced a SPAC merger, Brii and Amniotics launched ex-US IPOs, and Intellia, Cerevel and Kymera priced large follow-on offerings.
The concept of a parent company with operating subsidiaries is becoming increasing common in biotech. The first to do it, Daphne Zohar, who co-founded PureTech back in 2005, tells Scrip how the company has made that model work.
EU passes legislation allowing VAT exemption for coronavirus vaccines to make them more affordable, as two treatments for severe disease and “Long COVID” respectively enter Phase II trials.
- Medical Devices
- Site Specific
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
- Other Names / Subsidiaries
- Vedanta Biosciences, Inc.
- Alivio Therapeutics, Inc.
- resTORbio, Inc.
- Tal Medical
- Vor Biopharma